Endothelin News and Research

RSS

Endothelins are proteins that constrict blood vessels and raise blood pressure. They are normally kept in balance by other mechanisms, but when they are over-expressed, they contribute to high blood pressure (hypertension) and heart disease.

New research on EdnrB, Wnt signaling pathways could lead to therapies for skin pigment disorders

A pair of molecular signals controls skin and hair color in mice and humans — and could be targeted by new drugs to treat skin pigment disorders like vitiligo, according to a report by scientists at NYU Langone Medical Center.

29 Apr 2016

Researchers identify potential drug target in skin for itchy feeling

No matter the trigger -- bug bites, a medication side-effect or an itchy wound -- the urge to scratch can be a real pain. Researchers at the Duke University Medical Center have identified a potential drug target in the skin for that itchy feeling.

14 Mar 2016

New blood biomarkers could lead to better evaluation of treatment for patients with PAH

New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary arterial hypertension (PAH).

18 Jan 2016

14th APS symposium highlights role of endothelin in many biological functions

Endothelin (ET) is a peptide produced by cells in the blood vessels and has powerful vessel-constricting effects. Although endothelin is mainly associated with its role in blood pressure control and cardiovascular diseases, it continues to appear in other physiological functions and diseases.

4 Sep 2015

Endothelin system offers potential therapeutic target for ALS

Amyotrophic lateral sclerosis (ALS) is a disorder in which cells of the nervous system die, leading to muscle weakness that impacts breathing, movement and other physical functions.

4 Sep 2015

Study provides mechanism for EDNRB gene's role in adaptation to life at high altitudes

Ethiopians have lived at high altitudes for thousands of years, providing a natural experiment for studying human adaptations to low oxygen, a condition known as hypoxia. One factor that may enable Ethiopians to tolerate high altitudes and hypoxia is the endothelin receptor type B (EDNRB) gene.

4 Aug 2015

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines on the treatment of idiopathic pulmonary fibrosis (IPF) have been released by an international group of leading respiratory societies, The new guidelines, issued by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association, were published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

15 Jul 2015

Stopping cocaine use may lower levels of ET-1 protein that plays key role in coronary artery disease

For people who use cocaine, stopping or reducing cocaine use is associated with decreased levels of endothelin-1 (ET-1)--a protein that plays a key role in the development of coronary artery disease, reports a study in the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine.

14 Jul 2015

PAH diagnosis delayed for adult congenital heart disease patients

Pulmonary arterial hypertension is often not diagnosed in adult patients with congenital heart disease until 6 years or more after their symptoms first appear, research shows.

17 Jun 2015

Researchers call for earlier PAH diagnosis and treatment

A study has found that treatment of pulmonary arterial hypertension in patients younger than 55 years significantly improves their performance on the 6-minute walk test.

14 Apr 2015

Early decline in 6MWT distance predicts PAH worsening

Research shows that an early decline in 6-minute walk test distance can predict worsening of disease in patients with pulmonary arterial hypertension.

14 Apr 2015

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced today that its lead compound tacrolimus (SPI-026) has been granted Orphan Drug Designation by the U.S. Food & Drug Administration for the treatment of pulmonary arterial hypertension (PAH).

18 Mar 2015

UT Southwestern neuroscientists identify key brain cells that control circadian rhythms

UT Southwestern Medical Center neuroscientists have identified key cells within the brain that are critical for determining circadian rhythms, the 24-hour processes that control sleep and wake cycles, as well as other important body functions such as hormone production, metabolism, and blood pressure.

18 Mar 2015

Endothelin News and Research

New research on EdnrB, Wnt signaling pathways could lead to therapies for skin pigment disorders

Researchers identify potential drug target in skin for itchy feeling

New blood biomarkers could lead to better evaluation of treatment for patients with PAH

14th APS symposium highlights role of endothelin in many biological functions

Endothelin system offers potential therapeutic target for ALS

Study provides mechanism for EDNRB gene's role in adaptation to life at high altitudes

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Stopping cocaine use may lower levels of ET-1 protein that plays key role in coronary artery disease

PAH diagnosis delayed for adult congenital heart disease patients

Researchers call for earlier PAH diagnosis and treatment

Early decline in 6MWT distance predicts PAH worsening

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

UT Southwestern neuroscientists identify key brain cells that control circadian rhythms

Endothelin gene expression linked to vision loss in premature babies

Vascular receptor autoantibodies implicated in SSc-PAH

Targeted treatments may improve idiopathic PAH survival

CHEST guideline released for PAH

Olive oil supplements may counteract adverse cardiovascular effects of exposure to air pollution

Olive oil supplements may counteract adverse cardiovascular effects of air pollution

Ambrisentan cleared for use with phenprocoumon

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News